Search results for "OUTCOME"

showing 10 items of 5148 documents

The impact of psychopharmacology on contemporary clinical psychiatry.

2014

Clinical psychiatric evaluations of patients have changed dramatically in recent decades. Both initial assessments and follow-up visits have become brief and superficial, focused on searching for categorical diagnostic criteria from checklists, with limited inquiry into patient-reported symptomatic status and tolerability of treatments. The virtually exclusive therapeutic task has become selecting a plausible psychotropic, usually based on expert consensus guidelines. These guidelines and practice patterns rest mainly on published monotherapy trials that may or may not be applicable to particular patients but are having a profound impact, not only on modern psychiatric practice but also on…

medicine.medical_specialtyCanadaQuality Assurance Health CarePsychopharmacologyAlternative medicineMEDLINEpsychiatric treatmentspsychiatric diagnosisclinical psychiatryPsychiatric educationMedicineHumansPractice Patterns Physicians'PsychiatryRandomized Controlled Trials as TopicPsychiatryClinical psychiatryPsychotropic DrugsPractice patternsbusiness.industryMental DisordersExpert consensusChecklistPsychiatry and Mental healthTreatment OutcomeTolerabilityIn ReviewPsychopharmacologyClinical CompetenceGuideline AdherencebusinessForecastingCanadian journal of psychiatry. Revue canadienne de psychiatrie
researchProduct

Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A pros…

2015

We performed a multicenter study to validate the concept that a simple comprehensive geriatric assessment (CGA) can identify elderly, non-fit patients with diffuse large B-cell lymphoma (DLBCL) in whom curative treatment is not better then palliation, and to analyze potential benefits of treatment modulation after further subdividing the non-fit category by CGA criteria. One hundred and seventy-three patients aged > 69 treated with curative or palliative intent by clinical judgement only were grouped according to CGA into fit (46%), unfit (16%) and frail (38%) categories. Two-year overall survival (OS) was significantly better in fit than in non-fit patients (84% vs. 47%; p < 0.0001).…

medicine.medical_specialtyCancer ResearchMultivariate analysisLymphomaChemotherapeutic approaches; Immunotherapy; Lymphoma and Hodgkin disease; Hematology; Oncology; Cancer ResearchMEDLINEDisease-Free SurvivalInternal medicineComprehensive Assesment Diffuse large B cell lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicine80 and overLarge B-CellHumansProspective StudiesProspective cohort studyGeriatric AssessmentAgedAged 80 and overChemotherapeutic approachesbusiness.industryPalliative CareGeriatric assessmentHematologymedicine.diseasePrognosisDiffuseSurgeryLymphomaSettore MED/15 - MALATTIE DEL SANGUETreatment OutcomeMulticenter studyOncologyLymphoma and Hodgkin diseaseMultivariate AnalysisTreatment decision makingImmunotherapyLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Noninvasive diagnostic techniques of port wine stain.

2021

Port-wine stain (PWS) is a benign capillary malformation that most commonly occurs in the head and neck. It is present at birth and progresses over time. It is formed by progressive dilatation of post-capillary venules and is associated with hypertrophy and nodularity with increasing age, leading to cosmetic disfigurement and psychological aggravation. It is caused by genetic mosaicism in GNAQ and GNA11 genes. Histopathology is the gold standard for assessment of PWS but it is invasive and may cause scarring. Inadequate characterization of the lesions may predispose to inadequate treatment protocols as well as higher treatment dosages. Clinical evaluation of treatment efficacy is subjective…

medicine.medical_specialtyCapillary malformationVascular MalformationsPort-Wine StainDermatologyStain030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineOptical coherence tomographyMedicineHumansHemangioma CapillaryMicroscopy Confocalmedicine.diagnostic_testbusiness.industryUltrasoundInfant NewbornPort-wine stainGold standard (test)Laser Doppler velocimetrymedicine.diseaseTristimulus colorimeterTreatment Outcome030220 oncology & carcinogenesisRadiologybusinessJournal of cosmetic dermatologyREFERENCES
researchProduct

Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study.

2019

BACKGROUND AND AIMS Deciding when to repeat and when to stop transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) can be difficult even for experienced investigators. Our aim was to develop a survival prediction model for such patients undergoing TACE using novel machine learning algorithms and to compare it to conventional prediction scores, ART, ABCR and SNACOR. METHODS For this retrospective analysis, 282 patients who underwent TACE for HCC at our tertiary referral centre between January 2005 and December 2017 were included in the final analysis. We built an artificial neural network (ANN) including all parameters used by the aforementioned risk scores a…

medicine.medical_specialtyCarcinoma Hepatocellular610 MedizinPilot Projects03 medical and health sciences0302 clinical medicine610 Medical sciencesmedicineHumansIn patientInternal validationChemoembolization TherapeuticRetrospective StudiesHepatologyArtificial neural networkbusiness.industryLiver NeoplasmsPatient survivalClinical routinemedicine.diseaseTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyRadiologyNeural Networks ComputerbusinessArea under the roc curvePredictive modellingLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

2021

Summary Background Trans-arterial chemoembolization (TACE) is one first-line option therapy for patients with hepatocellular carcinoma (HCC) not suitable for surgical resection. Aims We evaluated the effects of sunitinib plus doxorubicin-TACE on bleeding or liver failure. Methods Seventy-eight patients with HCC were included in this randomized, double-blind study. They received one to three TACE plus either sunitinib or placebo four weeks out of six for one year. The occurrence of severe bleeding or liver failure was assessed during the week after the TACE. The safety and survival outcomes were evaluated. Results No bleeding complication was reported. One and two liver failures were respect…

medicine.medical_specialtyCarcinoma HepatocellularNeutropeniaurologic and male genital diseasesPlaceboPlacebo groupGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansChemoembolization TherapeuticHepatologybusiness.industrySunitinibLiver NeoplasmsGastroenterologyLiver failuremedicine.diseaseAcute toxicityTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDose reductionbusinessLiver Failuremedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct

Impact of margin status on long-term results of liver resection for hepatocellular carcinoma: single-center time-to-recurrence analysis

2020

Occult metastasis from the initial tumor and a de novo second primary hepatocellular carcinoma (HCC) were recognized as the main causes for the onset of early and late HCC recurrence, after liver resection (LR). This study aims to compare the time to recurrence after LR for HCC in which a margin ≤ 1 mm or > 1 mm was achieved. A single-center retrospective study involving 256 patients was conducted from June 2005 to June 2019. HCC patients resected with a radical surgical approach were investigated and stratified into groups A (resection margins ≤ 1 mm) and B (> 1 mm), as measured on final pathologic assessment. Kaplan–Meier estimators were used to estimate the probability of recurrenc…

medicine.medical_specialtyCarcinoma HepatocellularTime FactorsHepatocellular carcinomaHepatocellular carcinoma; Liver resection; Liver transplantation; Margin status; Outcome030230 surgerySingle CenterGastroenterologyGroup BMetastasis03 medical and health sciences0302 clinical medicineInternal medicineHepatocellular carcinoma Liver resection Liver transplantation Margin status Outcome Carcinoma Hepatocellular Liver Neoplasms Neoplasm Recurrence Local Neoplasms Second Primary Time Factors Hepatectomy Margins of ExcisionEpidemiologyHepatectomyHumansMedicineMargin statusPathologicalOutcomeLiver transplantationLiver resectionbusiness.industryProportional hazards modelLiver NeoplasmsMargins of ExcisionNeoplasms Second PrimaryRetrospective cohort studymedicine.diseaseSurgery030220 oncology & carcinogenesisHepatocellular carcinomaSurgeryNeoplasm Recurrence Localbusiness
researchProduct

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre

2019

BACKGROUND: The recurrence of hepatocellular carcinoma (HCC) is the strongest survival-limiting factor after liver transplantation (LT) in patients with HCC. In the face of donor organ shortage, it is necessary to identify factors associated with HCC recurrence in order to maximize the utility of the available grafts. OBJECTIVE: To study the phenomenon of HCC recurrence after LT at a European transplantation centre over the past 20 years. METHODS: Data from 304 HCC patients who underwent LT were prospectively recorded. Clinical and pathological factors were assessed for their association with recurrence. RESULTS: Fifty-one patients (16.8%) had HCC recurrence after LT. Patients exceeding the…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentEconomic shortageLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansIn patientneoplasmsProportional Hazards Modelsbusiness.industryLiver NeoplasmsGastroenterologyOriginal Articlesmedicine.diseasePrognosisdigestive system diseasesLiver TransplantationTransplantationEuropeTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessLiver cancer
researchProduct

Pathologic response to preoperative transarterial chemoembolization for resectable hepatocellular carcinoma may not predict recurrence after liver re…

2016

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentTreatment outcomeResection03 medical and health sciences0302 clinical medicineText miningResectable Hepatocellular CarcinomamedicinePathologic ResponseHepatectomyHumansChemoembolization TherapeuticRetrospective StudiesHepatologybusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyRadiologyHepatectomyNeoplasm Recurrence LocalbusinessHepatobiliarypancreatic diseases international : HBPD INT
researchProduct

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

2021

Abstract Aims  Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. Methods and results  The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to eith…

medicine.medical_specialtyCardiac & Cardiovascular SystemsINHIBITIONRATIONALEPlaceboHYPERKALEMIAMECHANISMSHyperkalaemiaChronic kidney diseaseInternal medicineDiabetes mellitusType 2 diabetes mellitusEND-POINTSPost-hoc analysismedicineHumansCanagliflozinRenal Insufficiency Chronic1102 Cardiorespiratory Medicine and HaematologySodium-Glucose Transporter 2 InhibitorsCanagliflozinOUTCOMESScience & Technologybusiness.industryType 2 Diabetes Mellitus1103 Clinical Sciencesmedicine.diseaseCardiovascular System & HematologyDiabetes Mellitus Type 2Serum potassiumCardiovascular System & CardiologyPotassiumCardiology and Cardiovascular MedicinebusinessComplicationLife Sciences & BiomedicineSGLT2 inhibitorsKidney diseasemedicine.drugEuropean Heart Journal
researchProduct

Feasibility of a MPR-based 3DTEE guidance protocol for transcatheter direct mitral valve annuloplasty.

2020

Objectives Several interventional approaches have been established for the treatment of severe mitral regurgitation (MR) in patients at elevated risk for surgery. Direct annuloplasty is a relatively novel option in transcatheter mitral valve repair dedicated to reverse pathology in specific subsets of MR. With regard to echocardiographic guidance, this procedure presents with higher efforts in comparison with edge-to-edge therapy to enable safe and exact positioning of the device's anchors; evidence on optimal peri-interventional imaging is sparse. We tested a specific 3D-echo-guidance protocol implementing single-beat multiplanar reconstruction (MPR) and evaluated its feasibility. Methods …

medicine.medical_specialtyCardiac CatheterizationMitral Valve Annuloplastycomputer.internet_protocol610 Medizin030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineMitral valve annuloplasty610 Medical sciencesMedicineFluoroscopyHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicineECHO protocolProtocol (science)Heart Valve Prosthesis ImplantationMitral regurgitationmedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyMultiplanar reconstructionTreatment OutcomeFeasibility StudiesTranscatheter mitral valve repairRadiologyCardiology and Cardiovascular MedicinebusinesscomputerEchocardiography (Mount Kisco, N.Y.)REFERENCES
researchProduct